Menu
We focus on immune checkpoint inhibitors – the key to unlocking new and effective cancer therapies. Our unique and innovative platform identifies novel immune checkpoints we can target with new drugs.
We combine cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the development of immuno-oncology therapies. Our lead drug is in a stage of IND-enabling studies and is planned to enter clinical Phase I in 2025.
We are committed to delivering pioneering solutions that directly influence patient care. Our discovery platform is patient-derived and able to discover new ways to fight cancer. Over 20% of the immune checkpoints we have discovered* have reached the stage of clinical trials by pharma companies.
*(IIA-supported research)
4C Biomed brings together a seasoned team of researchers and scientists with over a century of combined experience in biology, immunology and oncology, committed to the same goal – transforming cancer treatment.
